BB-1701
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for BB-1701, covering 2025-07-24 to 2026-03-20. Get the full timeline:
Most recent: Clinical Trial Update: A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer [Phase 2]